Frataxin genomic DNA locus (GAA repeat expansion) (FXN GAA repeat)

The FXN genomic DNA locus, specifically the pathogenic GAA trinucleotide repeat expansion within intron 1, is the primary genetic driver of Friedreich's ataxia (FA). In healthy individuals, this region contains fewer than 33 GAA repeats, whereas affected individuals typically possess 66 to over 1,000 repeats (NIH, 2023). This expansion induces the formation of heterochromatin and unusual DNA structures like R-loops and triplexes, which sterically hinder RNA polymerase II, leading to severe transcriptional silencing of the FXN gene (PubMed, 2021). Consequently, there is a deficiency of frataxin, a mitochondrial protein essential for iron-sulfur cluster biogenesis and cellular iron homeostasis (UniProt, 2024). Therapeutic strategies targeting this locus aim to restore frataxin levels through various modalities, including epigenetic modulators like HDAC inhibitors, antisense oligonucleotides to prevent transcriptional interference, and CRISPR-based gene editing to excise the expansion (Nature Reviews Drug Discovery, 2022). Addressing this target is critical as frataxin deficiency leads to progressive neurodegeneration, cardiomyopathy, and metabolic dysfunction.

Other names

FXN intron 1 GAA expansionFriedreich's ataxia locusGAA trinucleotide repeat expansionFrataxin geneFRDA locus

Transcriptional reactivation of the FXN gene by reversing epigenetic silencing, inhibiting R-loop formation, or direct excision of the GAA expansion using gene editing technologies.